Dr. John Cush RheumNow
1 year 3 months ago
EULAR 2025 – Day 3 Report
Highlights from Day 3 included presentations on imaging in vasculitis, a debate on treating high-risk pre-clinical RA, and EULAR Recommendations on ILD treatment, physical activity for arthritis, the EULAR disease activity score for antiphospholipid https://t.co/FAaj443wPX
Dr. John Cush RheumNow
1 year 3 months ago
Imaging and Early Detection in Psoriatic Arthritis
At EULAR 2025, there have been new developments in imaging in PsA. Two key poster presentations (POS0104 and OP0179) provide important insights into the role of imaging in the management and early detection of psoriatic https://t.co/41fgXj5WnN
Dr. John Cush RheumNow
1 year 3 months ago
Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/35cWYRehdd
Dr. John Cush RheumNow
1 year 3 months ago
Predictors and Outcomes in Systemic Sclerosis
The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will https://t.co/9dJn1qMQfy
Dr. John Cush RheumNow
1 year 3 months ago
Multinational metanalyses of 24 studies & 1,173,410 participants shows alcohol increases risk of hyperuricemia (OR 1.51) and gout (OR 1.81) - more so in males > females. Little effect of age, country, study type, type of alcohol, Dx criteria in regression analyses. https://t.co/NSYTppcKzV
Dr. John Cush RheumNow
1 year 3 months ago
Several studies have shown predictive value to monocyte counts in RA responses. UK study of 246 #RA pts showed pretreatment absolute monocyte count [ORadj 9.56; 1.61-59.86, p = 0.01) predicted bDMARD nonresponse @ 6 mos. Replicates other reports! https://t.co/GqGj8R0wq1 https://t.co/HJ7wFBoxGE
Dr. John Cush RheumNow
1 year 3 months ago
Steroids, Not JAKi, Are the Real Infection Risk
Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain.
https://t.co/rLpyo1UNjd https://t.co/bDfdLTEM1N
Dr. John Cush RheumNow
1 year 3 months ago
EULAR Daily Recap: Day 1 and 2
LIVE Daily Recap Day 1 & 2 – EULAR 2025 Coverage brings you the latest updates from EULAR 2025. Join Dr. Jack Cush, Dr. Mrinalini Dey, Dr. Antoni Chan, and Dr. Nelly Ziade as they discuss the biggest breakthroughs, standout sessions, and expert https://t.co/vkTo2MchsC
Advances in the treatment of rheumatoid arthritis, particularly the treat-to-target strategy and the introduction of effective DMARDs, have improved the management of inflammation in RA. However, improved inflammatory markers do not always translate into a resolution of patients’ symptoms or improvements in functional capacity. A recent pooled analysis from the CareRA and CareRA2020 randomized controlled trials shed new light on this
Dr. John Cush RheumNow
1 year 3 months ago
Using Combination csDMARDs in PsA
Dr. Eric Ruderman shares his insights on abstracts OP0093, OP0106, and POS0106, which discuss the effectiveness of combination csDMARD therapy, long-term outcomes of methotrexate and leflunomide, and a real-world treat-to-target strategy in https://t.co/Pv4YEyYShm
Dr. John Cush RheumNow
1 year 3 months ago
Social Determinants of Health in SLE
SDH, such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, https://t.co/Xf2bR7ap5m
Dr. John Cush RheumNow
1 year 3 months ago
Jokes Aside: The Impact of Laughter in RA
Dr. Aurelie Najm reports on POS0685, 'The Impact of Social Frailty and Physical Function on Laughter Frequency in Rheumatoid Arthritis Patients from a Multicenter Observational Study (T-FLAG)', presented at EULAR 2025 in Barcelona, https://t.co/z3tvqQmH96
Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was published in NEJM last month.
